



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
APR 27 2003
TECH CENTER 1600/2800

In Reply Application of:

Radzik et al.

Serial No. 09/901,425

Filed: 9 July 2001

For: MEDICAMENT INCORPORATION
MATRIX

To: Commissioner for Patents
Washington, D.C. 20231

) Art Unit: 1617

) Our Ref. 9896.139.3

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231

☐ facsimile transmitted to the Patent and Trademark Office

☐ hand delivered to the Patent and Trademark Office

on this 17 day of April 2003

By

Madeline E. Thompson

RESPONSE

This Response is filed in connection with the Office Action mailed March 17, 2003, the unextended period for response which is set to expire April 17, 2003. In addition to the restriction requirement previously made and responded to, including an exemplary election of species, the current Action now confirms the election of species requirement with respect to certain elected claims.


Applicant elects the following species, with traverse for the reasons set forth previously: methacrylic acid of claim 49; N-[3-(4-benzoylbenzoamido)propyl]methacrylamide of claim 53; acrylamide of claim 56; nucleic acids of claim 58; vancomycin of claim 59; vascular stents of claim 60; ethylene vinyl-acetate of claim 77; and stainless steels of claim 78.

The Commissioner is hereby authorized to charge any additional filing fees required to
Deposit Account No. 061910. A duplicate copy of this sheet is enclosed.

Dated: _____

17 APR 2003

Respectfully submitted,



Philip M. Goldman
Registration No. 31,162
Fredrikson & Byron, P.A.
4000 Pillsbury Center
200 South Sixth Street
Minneapolis, MN 55402-1425
(612) 492-7088
Customer No. 022859

PMG/Resp. to Restriction
2724065/2